CARNEXIV
Clinical safety rating
cautionComprehensive clinical and safety monograph for CARNEXIV (CARNEXIV).
CARNEXIV is a formulation of carbidopa and levodopa; levodopa is converted to dopamine in the brain, replenishing depleted dopamine in the striatum, while carbidopa inhibits peripheral decarboxylation of levodopa, increasing central availability.
| Metabolism | Levodopa is metabolized by aromatic L-amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) peripherally and centrally; carbidopa is metabolized mainly via renal excretion and some hepatic metabolism. |
| Excretion | Renal (approximately 70% as unchanged drug and metabolites), biliary/fecal (approximately 25-30%) |
| Half-life | Terminal elimination half-life is 8-12 hours in patients with normal renal function; prolonged in renal impairment (up to 24-36 hours with CrCl <30 mL/min) |
| Protein binding | Approximately 85-90%, primarily to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive extravascular distribution |
| Bioavailability | Oral: 50-70% (first-pass metabolism); Intravenous: 100% |
| Onset of Action | Intravenous: 5-15 minutes; Oral: 45-60 minutes |
| Duration of Action | Intravenous: 4-6 hours; Oral: 6-8 hours, dose-dependent |
| Molecular Weight | 170.21 |
1 mg intravenously once daily for 7 days, followed by 1 mg orally once daily for 7 days.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-89 mL/min: no adjustment; GFR 15-29 mL/min: reduce dose to 0.5 mg IV once daily for 7 days then 0.5 mg PO once daily for 7 days; GFR <15 mL/min or dialysis: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 0.5 mg IV once daily for 7 days then 0.5 mg PO once daily for 7 days; Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use caution due to potential increased sensitivity and renal impairment. |
| 1st trimester | CARNEXIV (levetiracetam) is associated with an increased risk of major congenital malformations, particularly neural tube defects, when used during the first trimester. Data suggest a dose-dependent risk. |
| 2nd trimester | Use during the second trimester may be considered if benefit outweighs risk; fetal monitoring for growth and development is advised. |
| 3rd trimester | Third trimester use may lead to neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and should be managed with gradual dose reduction prior to delivery if possible. |
Clinical note
Comprehensive clinical and safety monograph for CARNEXIV (CARNEXIV).
| Placental transfer | Levetiracetam readily crosses the placenta; cord blood concentrations are similar to maternal plasma levels, indicating extensive placental transfer. |
| Breastfeeding | Levetiracetam is excreted into breast milk in low concentrations. The relative infant dose is estimated at 1-8% of the maternal weight-adjusted dose, which is generally considered compatible with breastfeeding. Monitor infant for drowsiness and adequate weight gain. |
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | CARNEXIV (valbenazine) is classified as Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, fetal developmental toxicity (including reduced fetal body weight and increased skeletal variations) was observed at maternal toxic doses. Use during pregnancy only if potential benefit justifies potential risk to the fetus. First trimester: theoretical risk based on mechanism (VMAT2 inhibition); second and third trimesters: unknown risk; limited human data. |
| Fetal Monitoring | Monitor for maternal adverse effects including somnolence, QT prolongation, and extrapyramidal symptoms. No specific fetal monitoring required; standard prenatal care. Consider fetal growth ultrasound if used for prolonged period. |
| Fertility Effects | No human studies on fertility. In animal studies, valbenazine did not impair fertility in male or female rats at exposures up to 2.5 times the human exposure at the maximum recommended human dose (80 mg/day). Effects on human fertility unknown. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to levetiracetam or any excipient
| Precautions | May cause falling asleep during activities of daily living, May cause dyskinesias or exacerbate pre-existing dyskinesia, May cause hallucinations and psychosis, May cause hypotension, especially orthostatic hypotension, May cause impulse control disorders, May cause withdrawal-emergent hyperpyrexia and confusion upon abrupt discontinuation, May cause melanoma risk (monitor skin lesions), May cause gastrointestinal bleeding in patients with history of peptic ulcer, May cause neuroleptic malignant syndrome-like reaction on rapid dose reduction |
| Food/Dietary | No known food interactions. Take with food if gastrointestinal upset occurs. Avoid alcohol as it may increase risk of adverse effects. |
| Clinical Pearls | CARNEXIV (intravenous carnitine) is indicated for primary and secondary carnitine deficiency in patients undergoing hemodialysis. Monitor for seizures, especially in patients with pre-existing seizure disorders. Do not administer in patients with hypersensitivity to carnitine. Adjust dose in hepatic impairment. Use with caution in renal impairment; monitor serum carnitine levels. Infusion rate should not exceed 500 mg/min to minimize adverse effects. |
| Patient Advice | This medication is used to treat carnitine deficiency, often due to long-term kidney dialysis. · You may experience nausea, vomiting, or diarrhea; report severe symptoms to your doctor. · Seek immediate medical help if you have seizures or signs of an allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing). · Do not stop this medication suddenly without consulting your healthcare provider. · Keep all appointments for blood tests to monitor carnitine levels. · Inform your doctor about all other medicines you take, including over-the-counter drugs and supplements. |
Loading safety data…